[New approaches to the study of thrombocyte aggregation in patients with dilated cardiomyopathy].
A degree of platelet aggregation in patients with dilatation cardiomyopathy (DCMP) with different stages of heart failure (HF) was evaluated with the help of a highly sensitive aggregometer developed in the All-Union Cardiological Research Center AMS USSR. The main advantage of this modification was a possibility to study platelet aggregation in response to small doses of an inductor (e.g. less than 0.2 microM of ADP) that could not be done using routine methods. A significant rise of a degree of platelet aggregation was revealed in patients with 0-I,IIA stages of DCMP and IIB-III stages of HF in response to 0.1 microM of ADP. Platelet aggregation was enhanced with an increase in a HF stage. The addition of a higher concentration of ADP (0.2-0.5 microM) and the platelet aggregation factor (5 and 25 nM) revealed no rise of platelet aggregation in patients with 0-I stages of DCMP and IIA stage of HF. Only in patients with stages IIB-III of HF was a platelet aggregation index significantly raised in response to 0.2 and 0.5 microM of ADP but to a much lesser degree than in the addition of 0.1 microM of ADP.